The European Medicines Agency has added 11 new products to its latest monthly list of medicines that are under review for potential pan-EU marketing authorization, including the investigational drugs concizumab, elranatamab and talquetamab.
Concizumab is Novo Nordisk’s anti-tissue factor pathway inhibitor (TFPI) antibody for hemophilia A or B.








